p.80 抽出テキスト

• Long-term trials on exercise in patients with HF. • Studies to determine personalized approach for palliative care to improve patient-centred outcomes. • Models of care that incorporate contemporary patients with HF and the wider multidisciplinary team including cardio-kidney-metabolic professionals in HF care. • Patient selection for telemonitoring. (9) Specific conditions

• Randomized clinical trials for the treatment of peripartum cardiomyopathy. • Head-to-head comparison between different diseasemodifying drugs in ATTR-CA. • Evidence for the combined use of disease-modifying drugs in ATTR-CA. • Evidence for gene editing and antibodies for the removal of amyloid deposits. • Efficacy of traditional HF therapies in patients with CA. • Identification of patients with ATTR-CA who could benefit from device therapy (e.g. ICD/CRT). • Data collection to support advice on screening for TTR gene carriers—when to initiate and follow-up interval.

15 Evidence tables

Evidence tables are available at European Heart Journal online.

16 Data availability

No new data were generated or analysed in support of this research.

17 Author information

Author/Task Force Member Affiliations: Anne-Christine Ruwald, Department of Cardiology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark; Daniela Tomasoni, Cardiology Unit, ASST Spedali Civili di Brescia, Brescia, Italy, and Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Stockholm, Sweden; Lisa J. Anderson, Cardiology Clinical Academic Group, St George’s University Hospitals NHS Foundation Trust, London, United Kingdom, and Cardiovascular and Genomic Research Institute, City St George’s University of London, London, United Kingdom; Charlotte Andersson, Mass General Brigham Heart and Vascular Institute and Harvard Medical School, Boston, MA, United States of America; Jasper J. Brugts, Cardiology Department, Erasmus MC University Medical Center, Cardiovascular Institute, Rotterdam, Netherlands; Ovidiu Chioncel, Emergency Institute for Cardiovascular Diseases ‘Prof. Dr. C.C. Iliescu’, Bucharest, Romania and University of Medicine Carol Davila, Bucharest, Romania; Erwan Donal, Cardiology Department-LTSI-Inserm 1099, CHU Rennes—Université Rennes, Rennes, France; Peter Ferdinandy, Department of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest, Hungary, and Pharmahungary Group, Szeged, Hungary; Pardeep S. Jhund, School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, United Kingdom; Francisco Leyva, Aston Medical School, Aston University, Birmingham, United Kingdom, and Department of Cardiology, University Hospitals Birmingham, Queen Elizabeth, Birmingham, United Kingdom; Roberto Lorusso, Cardio-Thoracic Surgery, Maastricht University Medical Centre (MUMC), Maastricht, Netherlands, and Cardiovascular Research Institute Maastricht (CARIM), Maastricht, Netherlands; Michael Madigan (Ireland), ESC Patient Forum, Sophia Antipolis, France; Wilfried Mullens, Cardiology Department, Ziekenhuis Oost Limburg, Genk, Belgium, and Faculty of Medicine and Life Sciences, University Hasselt, Diepenbeek, Belgium; Stefania Paolillo, Department of Advanced Biomedical Sciences, Section of Cardiology, Federico II University of Naples, Naples, Italy; Nicola Ryan, Department of Cardiology, Aberdeen Royal Infirmary, Aberdeen, United Kingdom; Maggie Simpson, Edinburgh Medical School, University of Edinburgh, Edinburgh, United Kingdom; Holger Thiele, Cardiology Department, Heart Center Leipzig at Leipzig University, Leipzig, Germany, and Leipzig Heart Science, Leipzig, Germany; Jens Jakob Thune, Department of Cardiology, Copenhagen University Hospital— Bispebjerg and Frederiksberg, Copenhagen, Denmark, and Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark; Emeline M. Van Craenenbroeck, Cardiology Department, Antwerp University Hospital, Edegem, Belgium, and Cardiovascular Diseases, GENCOR, University of Antwerp, Belgium; Linda W. Van Laake, Cardiology Department, University Medical Center Utrecht, Utrecht, Netherlands, and Utrecht University, Utrecht, Netherlands, and Transplantation Center, University Medical Center Utrecht, Utrecht, Netherlands; Mariette Verbakel (Netherlands), ESC Patient Forum, Sophia Antipolis, France.

18 Appendix

ESC Guidelines Advisory Group Includes Document Reviewers and ESC National Cardiac Societies. Document Reviewers: Christina Christersson (CPG Review Coordinator) (Sweden), Massimo F. Piepoli (CPG Review Coordinator) (Italy), Ana Abreu (Portugal), Suleman Aktaa (United Kingdom), Folkert W. Asselbergs (Netherlands), Michael A. Borger (Germany), Giuseppe Boriani (Italy), Margarita Brida (Croatia), Robert A. Byrne (Ireland), Claudio Ceconi (Italy), Christina Chrysohoou (Greece), Kevin Damman (Netherlands), Jean-Claude Deharo (France), Victoria Delgado (Spain), Fernando Dominguez (Spain), Gloria Färber (Germany), Daniel Fernandez-Berges (Spain), Marc Ferrini (France), Estelle Gandjbakhch (France), Luna Gargani (Italy), Bettina Heidecker (Germany), Borja Ibanez (Spain), Massimo Imazio (Italy), Stefan James (Sweden), Ulf Landmesser (Germany), Gregory Y.H. Lip (United Kingdom), Lars H. Lund (Sweden), Sharon MacDonald (United Kingdom), John William McEvoy (Ireland), Lorenzo Menicanti (Italy), Borislava Mihaylova (United Kingdom), Inge Moelgaard (Denmark), Christian E. Mueller (Switzerland), Lis Neubeck (United Kingdom), Daniela Pini (Italy), Evgenij V. Potapov (Germany), Anne-Catherine Pouleur (Belgium), Eva Prescott (Denmark), Amina Rakisheva (Kazakhstan), Bianca Rocca (Italy), Xavier Rossello (Spain), Anna Sannino (Germany), Hatem Soliman Aboumarie (United Kingdom), Felix C. Tanner (Switzerland), Izabella Uchmanowicz (Poland), Mattias Van Downloaded from academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehag100/8766302 by guest on 31 August 2026